236 related articles for article (PubMed ID: 30499118)
1. Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Majera D; Skrott Z; Bouchal J; Bartkova J; Simkova D; Gachechiladze M; Steigerova J; Kurfurstova D; Gursky J; Korinkova G; Cwiertka K; Hodny Z; Mistrik M; Bartek J
Prostate; 2019 Mar; 79(4):352-362. PubMed ID: 30499118
[TBL] [Abstract][Full Text] [Related]
2. Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET.
Kanellis DC; Zisi A; Skrott Z; Lemmens B; Espinoza JA; Kosar M; Björkman A; Li X; Arampatzis S; Bartkova J; Andújar-Sánchez M; Fernandez-Capetillo O; Mistrik M; Lindström MS; Bartek J
Cell Death Differ; 2023 Jul; 30(7):1666-1678. PubMed ID: 37142656
[TBL] [Abstract][Full Text] [Related]
3. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
4. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
[TBL] [Abstract][Full Text] [Related]
6. Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
Yalon M; Tuval-Kochen L; Castel D; Moshe I; Mazal I; Cohen O; Avivi C; Rosenblatt K; Aviel-Ronen S; Schiby G; Yahalom J; Amariglio N; Pfeffer R; Lawrence Y; Toren A; Rechavi G; Paglin S
PLoS One; 2016; 11(5):e0155711. PubMed ID: 27196668
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET.
Buchtova T; Skrott Z; Chroma K; Rehulka J; Dzubak P; Hajduch M; Lukac D; Arampatzis S; Bartek J; Mistrik M
Mol Oncol; 2022 Apr; 16(7):1541-1554. PubMed ID: 34632694
[TBL] [Abstract][Full Text] [Related]
11. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
12. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
13. Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
Chang T; Lian Z; Ma S; Liang Z; Ma X; Wen X; Wang Y; Liu R
Prostate; 2023 Apr; 83(5):470-486. PubMed ID: 36576015
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β.
Sharma V; Verma V; Lal N; Yadav SK; Sarkar S; Mandalapu D; Porwal K; Rawat T; Maikhuri JP; Rajender S; Sharma VL; Gupta G
Mol Carcinog; 2016 Nov; 55(11):1843-1857. PubMed ID: 26599461
[TBL] [Abstract][Full Text] [Related]
16. Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.
Mansour WY; Tennstedt P; Volquardsen J; Oing C; Kluth M; Hube-Magg C; Borgmann K; Simon R; Petersen C; Dikomey E; Rothkamm K
Sci Rep; 2018 Mar; 8(1):3947. PubMed ID: 29500400
[TBL] [Abstract][Full Text] [Related]
17. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.
Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG
Clin Cancer Res; 2012 Feb; 18(4):1015-27. PubMed ID: 22114138
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells.
Loffelmann M; Škrott Z; Majera D; Štarha P; Kryštof V; Mistrík M
Eur J Med Chem; 2023 Dec; 261():115790. PubMed ID: 37690264
[TBL] [Abstract][Full Text] [Related]
19. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
Chroma K; Mistrik M; Moudry P; Gursky J; Liptay M; Strauss R; Skrott Z; Vrtel R; Bartkova J; Kramara J; Bartek J
Oncogene; 2017 Apr; 36(17):2405-2422. PubMed ID: 27841863
[TBL] [Abstract][Full Text] [Related]
20. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
